The first carbon monoxide-releasing molecules (CO-RMs) based on mu2-alkyne dicobalt(0)hexacarbonyl complexes are reported. The alkyne substituents significantly affect the rate of CO-release, cytotoxicity and cell viability. Mechanistic studies provide insight into the CO-RM activation pathways.
No takes yet. Share an insight, caveat, or question.
Atkin et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: